Solid dispersion forms of rifaximin

1. A method of preventing complications of liver disease in a subject having liver cirrhosis, comprising administering to the subject a pharmaceutical composition comprising

from about 16 wt % to about 18 wt % rifaximin;

from about 16 wt % to about 18 wt % HPMC-AS;

from about 1 wt % to about 2 wt % poloxamer 407;

from about 8 wt % to about 10 wt % croscarmellose sodium;

from about 49 wt % to about 51 wt % microcrystalline cellulose;

from about 0.15 wt % to about 0.25 wt % colloidal silicon dioxide; and

from about 0.45 wt % to about 0.55 wt % magnesium stearate, wherein the total amount of rifaximin is 40 mg and wherein the complications of liver disease are selected from the group consisting of hepatic encephalopathy (HE), esophageal variceal bleeding (EVB), spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS).

2. The method of claim 1 , wherein the composition is an immediate release composition.

3. The method of claim 1 , wherein the composition is in the form of a tablet.

4. The method of claim 2 , wherein the composition is in the form of a tablet.

5. The method of claim 1 , wherein the complication of liver disease is hepatic encephalopathy (HE).

6. The method of claim 1 , wherein the complication of liver disease is esophageal variceal bleeding (EVB).

7. The method of claim 1 , wherein the complication of liver disease is spontaneous bacterial peritonitis (SBP).

8. The method of claim 1 , wherein the complication of liver disease is hepatorenal syndrome (HRS).

9. The method of claim 2 , wherein the complication of liver disease is hepatic encephalopathy (HE).

10. The method of claim 2 , wherein the complication of liver disease is esophageal variceal bleeding (EVB).

11. The method of claim 2 , wherein the complication of liver disease is spontaneous bacterial peritonitis (SBP).

12. The method of claim 2 , wherein the complication of liver disease is hepatorenal syndrome (HRS).